Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Institutes (C.R.M.), College of Pharmacy, University of Florida, Gainesville, Florida.
Departments of Pharmacodynamics (S.O., J.L.W., M.E.R., L.F.R., L.R.G.-J., A.P., A.E.P., V.A.T., N.P.H., T.B., M.R.W., V.L.C.P., L.R.M., T.H.) and Medicinal Chemistry (S.O., F.L., J.D.F., M.L.C., M.M., C.L.-L., C.R.M.), and Translational Drug Development Core, Clinical and Translational Sciences Institutes (C.R.M.), College of Pharmacy, University of Florida, Gainesville, Florida
J Pharmacol Exp Ther. 2021 Mar;376(3):410-427. doi: 10.1124/jpet.120.000189. Epub 2020 Dec 31.
Relationships between -opioid receptor (MOR) efficacy and effects of mitragynine and 7-hydroxymitragynine are not fully established. We assessed in vitro binding affinity and efficacy and discriminative stimulus effects together with antinociception in rats. The binding affinities of mitragynine and 7-hydroxymitragynine at MOR (K values 77.9 and 709 nM, respectively) were higher than their binding affinities at -opioid receptor (KOR) or -opioid receptor (DOR). [S]guanosine 5'--[-thio]triphosphate stimulation at MOR demonstrated that mitragynine was an antagonist, whereas 7-hydroxymitragynine was a partial agonist (E = 41.3%). In separate groups of rats discriminating either morphine (3.2 mg/kg) or mitragynine (32 mg/kg), mitragynine produced a maximum of 72.3% morphine-lever responding, and morphine produced a maximum of 65.4% mitragynine-lever responding. Other MOR agonists produced high percentages of drug-lever responding in the morphine and mitragynine discrimination assays: 7-hydroxymitragynine (99.7% and 98.1%, respectively), fentanyl (99.7% and 80.1%, respectively), buprenorphine (99.8% and 79.4%, respectively), and nalbuphine (99.4% and 98.3%, respectively). In the morphine and mitragynine discrimination assays, the KOR agonist U69,593 produced maximums of 72.3% and 22.3%, respectively, and the DOR agonist SNC 80 produced maximums of 34.3% and 23.0%, respectively. 7-Hydroxymitragynine produced antinociception; mitragynine did not. Naltrexone antagonized all of the effects of morphine and 7-hydroxymitragynine; naltrexone antagonized the discriminative stimulus effects of mitragynine but not its rate-decreasing effects. Mitragynine increased the potency of the morphine discrimination yet decreased morphine antinociception. Here we illustrate striking differences in MOR efficacy, with mitragynine having less than 7-hydroxymitragynine. SIGNIFICANCE STATEMENT: At human -opioid receptor (MOR) in vitro, mitragynine has low affinity and is an antagonist, whereas 7-hydroxymitragynine has 9-fold higher affinity than mitragynine and is an MOR partial agonist. In rats, intraperitoneal mitragynine exhibits a complex pharmacology including MOR agonism; 7-hydroxymitragynine has higher MOR potency and efficacy than mitragynine. These results are consistent with 7-hydroxymitragynine being a highly selective MOR agonist and with mitragynine having a complex pharmacology that combines low efficacy MOR agonism with activity at nonopioid receptors.